New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

A new investigational medication known as amycretin has shown significant potential in promoting weight loss, according to ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

The new weight-loss tablet was developed in a lab and is based on “a type of β2 agonist.” As explained in the news release: ...

By Vijay Kumar Malesu A new trial reveals that once-weekly amycretin injections help adults shed more than 20% of their body weight, marking a major leap forward in obesity care and metabolic health.

Amycretin — a novel obesity treatment that targets both GLP-1 and amylin receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which targets both GLP-1 and amylin receptors to help control blood sugar and ...